Blume-Jensen Peter insider trades
Blume-Jensen Peter has filed 21 Form 4s with the SEC that we hold, all for Acrivon Therapeutics, Inc. (ACRV), as President and CEO, Director. Across all of them we count 1 purchase worth $82.3K and 3 sales worth $34.4K reported on Form 4. In the last 12 months: 1 purchase ($82.3K) and 3 sales ($34.4K). The largest single trade was a purchase of 49,000 shares of Acrivon Therapeutics, Inc. worth $82.3K, dated 2026-01-14. Of 3 sales filed since we began reading the 10b5-1 checkbox, 0 (0%) were marked as made under a 10b5-1 trading plan. The first filing on our record is dated 2022-11-16 and the latest 2026-08-27.
Acrivon Therapeutics, Inc. (ACRV)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2026-01-14 | P, purchase reported on Form 4 | 49,000 | $82.3K | 2026-01-16 |
| 2026-08-18 | S, sale reported on Form 4 | 1,229 | $2.5K | 2026-08-20 |
| 2026-08-18 | S, sale reported on Form 4 | 484 | $973 | 2026-08-20 |
| 2026-08-25 | S, sale reported on Form 4 | 14,036 | $31.0K | 2026-08-27 |
Counted from the Form 4 filings this reporting owner (SEC CIK 1950499) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms